India to extend its global presence on pharmaceutical market with BRICS plus membership
The VIII International Conference on Antimonopoly Policy at Moscow's Skolkovo Innovation Center focused on enforcing competition laws in the pharmaceutical market. Representatives from Indian antitrust authorities expressed intent to support competition laws enforcement in information disclosure and patent regulation against global pharmaceutical monopolies. Key Points
Economic TimesIndia has made significant progress in increasing access to vaccines in recent years: Vivek Sehgal, DG, OPPI
Immunisation currently prevents 3.5-5 million deaths every year from diseases like diphtheria, tetanus, pertussis, influenza and measles, as per WHO data. Key Points
FinancialexpressChina’s covid drugmakers' shares surge amid concern over new wave
China covid: Xinxiang Tuoxin pharmaceutical Co. jumped as much as 20% in Shenzhen, while Hybio pharmaceutical Co. rallied 15%. | World News Key Points
Hindustan TimesQuality is a top priority today, regulators are working closely to ensure this: Health Minister Mandaviya
The event was inaugurated by Samir Mehta, Chairman, Torrent Pharmaceuticals and President, IPA. Meanwhile, S Aparna, Secretary, Department of Pharmaceuticals, GoI, delivered the keynote address during the inaugural session. Key Points
FinancialexpressForeign pharma firms seek clarity on doctors attending events abroad under new 'ethical practices' rules
Drugmakers often arrange international conferences to expound medical knowledge of doctors. Detractors of this practice say this adds to cost of medicines, thereby, affecting common man. Key Points
ThePrint
India orders new drug-making standards after overseas deaths
The Indian government has issued a notification requiring pharmaceutical companies to adhere to new manufacturing standards in response to concerns over the quality and safety of drugs. The move comes in the wake of overseas deaths linked to Indian-made drugs since 2022, prompting increased scrutiny of the $50 billion pharmaceutical industry. Key Points
Economic TimesTakeda announces voluntary withdrawal of lung cancer therapy
Takeda pharmaceutical (4502.T) said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal in a late-stage study. Key Points
ReutersFundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potent
There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Will this correction continue even longer ? The probability is high. But then every few months there is a phase of volatility which comes to market and stocks and sector corrects. Some more, some less. Instead of focusing on how much nifty or bank nifty or any other index is down or up, focus on the fact that whether the sector or company is doing well and will it do well in future because the fundamental operating matrix of that sector has changed for better. Because volatile phases come and go, changes in the operating matrix don't happen every day. pharmaceutical is one sector where there is a fundamental change taking place and it has happened after 8 to 10 years of restructuring and painful readjustment. So, it would be worthwhile to have them on watchlist. Key Points
Economic TimesEU proposal may accelerate pharma innovation decline, industry group says
A major pharmaceutical rules overhaul, proposed by the European Commission in April, could see Europe's share in global research and development contract by a third to 21% by 2040 translating to 2 billion euros ($2.15 billion) per year in lost investment, industry group EFPIA said on Monday. Key Points
ReutersValiant Laboratories shares list at 16% premium over issue price
Valiant Labs is an active pharmaceutical ingredient (API/bulk drug manufacturing company, with a focus on producing Paracetamol. APIs serve as raw materials for manufacturing finished dosage forms or formulations. Key Points
Economic Times
Valiant Laboratories IPO opens today. Should you subscribe to the issue?
The pharmaceutical API industry in India is ranked third-largest globally in terms of volume. It is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well as export markets. Key Points
Economic TimesGerman pharma major Bayer stops business in Pakistan: Report
Bayer, one of the world's biggest pharmaceutical firms, is closing its business in Pakistan in the wake of a protest from local employees who demanded the company pay them between five and eight years' worth of salary. Bayer has sold the company's factory to a local firm that has promised to keep existing workers on the payroll for at least two years. Key Points
Economic TimesMeet Murali Divi, the billionaire scientist who has a net worth of $5.8 billion; Know about his journey & lifestyle
U.S.-trained scientist Murali Divi founded generics maker Divi's Laboratories 33 years ago as a drug research firm. Key Points
FinancialexpressSun Pharma recalls 55K bottles of generic medication in US
Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food &... Key Points
The Tribune IndiaAkums Drugs files draft IPO papers with Sebi; eyes Rs 680 cr via fresh issue
The company is looking to raise Rs 136 crore through a pre-IPO placement. If such placement is undertaken, then fresh issue size will be reduced. Proceeds from the fresh issue will be used to repay debt, fund working capital requirements of the company, pursue inorganic growth initiatives through acquisition and for general corporate purposes. Key Points
Economic Times
Pharma MSMEs can get govt help to upgrade facilities
The health and family welfare ministry has made good manufacturing practices mandatory for pharma companies. A recent notification by the ministry covered the revised Schedule M rules for good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products, with provisions for an annual product quality review, risk management and a quality system. Key Points
Economic TimesMankind Pharma Block Deal: Chrys Capital divests stake worth ₹3,200 crore, Beige sells 1.44 crore shares
Kotak Mutual Funds acquired 2 million shares in the pharmaceutical company at a price of ₹1,832.30 per share. Key Points
mintParacetamol maker Granules India' Q1 profit hurt by cyber attack disruptions
Granules India Ltd (GRAN.NS), the maker of paracetamol and ibuprofen pain relievers, reported a 62.5% fall in first-quarter profit on Wednesday, as a cyber security incident significantly disrupted operations. Key Points
ReutersDrug pricing regulator looking to make vital health supplements more affordable
The National pharmaceutical Pricing Authority (NPPA) proposes to invoke extraordinary powers in public interest, under para 19 of Drugs Prices Control Order (DPCO) 2013, for an indefinite period to make them more affordable to patients, it has said. The NPPA has been invoking para 19 in certain cases in the public interest to make drugs affordable with indefinite period, said the minutes of the authority meeting. ET has seen the minutes of the meeting. Key Points
Economic TimesIndian firm Marion Biotech used toxic industrial-grade ingredient in syrup: Sources
The company, Marion Biotech, bought the ingredient - propylene glycol (PG) - from trader Maya Chemtech India, as reported by Reuters. But Maya did not have a licence to sell pharmaceutical-grade materials and dealt in industrial-grade only, according to a source at the firm with knowledge of the Marion investigation. Key Points
Economic Times
View: India's drug industry needs a major overhaul
Despite campaigns for regulatory reform since a corruption and fraud scandal in 2013, India's Central Drugs Standard Control Organisation remains unreformed, and a law on drug recalls has been under discussion since 1976 without resolution. Experts call for overhaul, transparency, and accountability to ensure safer manufacturing and export practices. Key Points
Economic TimesIndia's top drugmaker Sun Pharma beats Q2 profit view
Sun pharmaceutical Industries (SUN.NS), India's largest drugmaker by revenue, reported a bigger-than-expected rise in second-quarter profit on Wednesday, driven by strong sales in its domestic and U.S. formulation businesses. Key Points
Reuters5 best mutual funds in the pharma and healthcare sector; check full list
The Indian pharmaceutical sector holds significant growth potential, yet it is crucial to acknowledge the accompanying risks and uncertainties. Before making any commitments to invest in a pharma fund, thorough research is imperative. Key Points
mintAntibiotic resistance a looming, lethal global threat
Antibiotic-resistant bacteria present a deadly threat to our health. But making new drugs just isn’t profitable. | Health Key Points
Hindustan TimesUS Senator Elizabeth Warren expresses 'disappointment' in FTC's Amgen decision
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen (AMGN.O) to move forward with its acquisition of Horizon Therapeutics. Key Points
Reuters
US says prostitution ring counted politicians, tech execs, lawyers as clients
According to charging documents, the defendants used high-end apartment complexes as brothels in Cambridge and Watertown, Massachusetts, and Fairfax and Tysons, Virginia. US prosecutors on Wednesday charged three people with running a high-end brothel network out of apartment complexes in greater Boston and northern Virginia whose customers included elected officials, tech and pharmaceutical executives, lawyers, professors and military officers. Key Points
The Tribune IndiaIndia's Alembic Pharma Q2 profit roughly in-line with estimates
India's Alembic Pharmaceuticals (ALEM.NS) on Tuesday reported second-quarter profit roughly in line with estimates, as higher sales in its domestic and overseas markets offset a jump in expenses. Key Points
ReutersBlue Jet Healthcare shares list at 10% premium over issue price
The IPO of Blue Jet Healthcare was booked nearly 8 times at close, led by healthy interest from NIIs and QIBs. The IPO was priced in the range of Rs 329-346. Blue Jet Healthcare develops and supplies specialty pharmaceutical and healthcare ingredients and intermediates under a contract development and manufacturing organization (CDMO) business model. Key Points
Economic TimesRoche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche (ROG.S) has settled a patent lawsuit against U.S. biotech firm Biogen (BIIB.O) over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court. Key Points
ReutersNot geopolitical tension, worried more about higher for longer rates: Sampath Reddy
“The domestic facing sectors have been currently doing much better especially the financials. The export-oriented sectors, especially IT, are still facing challenges in terms of overall growth. That is why the domestic facing sectors are much preferred. But within the exports, especially the pharmaceutical export, the generic pharmaceutical exports segment continues to do well. ” Key Points
Economic Times/cloudfront-us-east-2.images.arcpublishing.com/reuters/EPX5FMVD6FNKRNWE2FC637B57A.jpg)
Sun Pharma Q1 profit falls as higher costs hit top Indian drugmaker
Sun pharmaceutical Industries (SUN.NS) posted a nearly 2% fall in first-quarter profit on Thursday as higher expenses offset demand for its drugs and related products. Key Points
ReutersStock Radar: FDC hit fresh 52-week high in June; time to buy more or book profits?
Experts predict that FDC, a pharmaceutical company, may reach Rs 400 in the medium term, provided the stock closes above strong resistance at Rs 320. While it hit a 52-week high of Rs 322.70 on June 12, the stock is still showing positive signs, having rallied over 2% in a week and over 18% in the last three months. Key Points
Economic TimesPharma stock recommends a final dividend of ₹10 and a one-time special dividend of ₹37.50: Do you own?
During today's closing session, the market capitalization of Novartis India, a small-cap pharmaceutical business, was ₹1,650.09 Cr. Key Points
mintU.S.FDA observation for Dr. Reddy’s unit
Dr. Reddy’s Laboratories has been issued a Form 483 with one observation by the United States Food and Drug Administration following an inspection of the company’s active pharmaceutical ingredient (API) manufacturing facility in Bollaram, Hyderabad. Key Points
The Hindu